Wu Capital has led a series A round for Korro Bio, whose RNA editing technology was developed at UChicago-affiliated Marine Biological Laboratory.
Korro Bio, a US-based RNA therapy developer based on Marine Biological Laboratory research, raised $91.5m yesterday in a series A round led by Wu Capital. Alexandria Venture Investments, the strategic investment division of life sciences real estate investment trust Alexandria Real Estate Equities, backed the round alongside Atlas Venture, New Enterprise Associates, Qiming Venture Partners…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
